About us
Uniogen is dedicated to advancing the field of cancer diagnostics, infectious disease diagnostics, and biotechnology instrumentation and life science applications through innovative research and development.
Uniogen is a Finnish pioneer in the field of in vitro diagnostics (IVD) and life sciences. The company is developing, manufacturing and selling diagnostic tests and laboratory equipment, and is a provider of development and manufacturing services of laboratory instruments and reagents for global IVD and life science industry.
For early cancer detection Uniogen is developing a novel ovarian cancer specific blood test aiming to provide unprecedented sensitivity and specificity for ovarian cancer. Ovarian cancer assay is the company’s most advanced test of the new, proprietary cancer diagnostic test portfolio currently under development.
GenomEra rapid PCR tests for SARS-CoV-2 / COVID-19 form a significant part of Uniogen’s current business. We also provide laboratory instruments and tests for the detection of anti-SARS-CoV-2 antibodies and other diseases through contract development and manufacturing services. Our Upcon™ labeling system, coupled with state-of-the-art laboratory instruments and flexible software, brings high sensitivity and superior performance to point-of-care testing.
“Uniogen core expertise and future growth areas are: cancer diagnostics, diagnostics of infectious diseases, instrumentation, and contract development and manufacturing of IVD and life science products.”
We are currently developing our first proprietary test based on unique glycovariant immunoassay for the early detection of ovarian cancer. Ground-breaking for the market, we are also developing a complete solution for point-of-care testing, integrating immunoassay and PCR testing. This unique system will enable the diagnostics of several diseases simultaneously with a single, versatile, and easy-to-use device — virtually in any healthcare setting.
Uniogen was established when Abacus Diagnostica, a frontrunner in molecular testing and rapid PCR tests, Kaivogen, a specialist in immunoassays and antibody testing, and Labrox, an innovator of high-end laboratory instruments and diagnostic readers, joined forces in 2022. The company is headquartered in Turku, Finland, and employs around 80 life science professionals. Uniogen developed and manufactured products are sold in close to 100 countries around the world.
“Together, we have combined immunoassay, PCR and instrumentation expertise enabling us to develop new innovative diagnostics products by addressing unmet customer needs. Uniogen’s new products currently under development include e.g. high performance assay for early detection of ovarian cancer, and innovative solutions for point-of-care testing. The cancer testing portfolio and , which will open great growth opportunities for us in the global diagnostics market.”
For more information on Uniogen’s services, please contact us here.